Depression Nasal spray

FDA Approves ‘Spravato’ Nasal Spray

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

Popular Science · 1d

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

PopSugar · 12h

Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

IFLScience2h

FDA Approves First-Ever Standalone Therapy For Treatment-Resistant Depression

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

J&J’s Spravato receives FDA label expansion for depression monotherapy

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

FDA Approves ‘Spravato’ Nasal Spray

Trending now

Related topics